Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 20Ovarian Neoplasms 2Breast Cancer Metastatic 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1HR+/HER2- Advanced Breast Cancer 1HR Positive HER2 Negative Advanced Breast Cancer 1HER2-positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasm Female 1Breast Diseases 1Brain Neoplasms 1Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed 1Advanced Breast Cancer 1

Interventions

Fulvestrant 5Letrozole 3Capecitabine 3ribociclib 2exemestane 2dalpiciclib 2apatinib 2Irinotecan 2Gemcitabine 2Anastrozole 2tusamitamab ravtansine 1trastuzumab deruxtecan 1sacituzumab govitecan 1pegfilgrastim 1palbociclib 1margetuximab 1irinotecan sucrosofate 1fluzoparib 1abemaciclib 1Vinorelbine 1Trastuzumab 1Tamoxifen 1Paclitaxel 1Liposomes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Breast Cancer Metastatic × dalpiciclib × Clear all
NCT05759546 2024-02-06

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Fudan University

Phase 2 Recruiting
200 enrolled
Breast

Breast Cancer Metastatic

NCT05759572 2024-02-06

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

Fudan University

Phase 2 Recruiting
145 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡